Fierce Pharma April 17, 2024
In addition to their acclaimed efficacy against diabetes and obesity, GLP-1 drugs are gaining traction for their potential to treat a variety of other common disorders.
Add another to the list as two trials have shown that Eli Lilly’s weight loss product Zepbound (tirzepatide) can help patients overcome obstructive sleep apnea (OSA), a condition that disrupts breathing during sleep and has been diagnosed in 20 million in the United States.
The phase 3 studies, both a year long, demonstrated that patients taking tirzepatide had about 30 fewer sleep apnea events per hour than those on placebo. Both trials—one for patients using continuous positive airway pressure (CPAP) and the other without—met all primary and secondary endpoints.
All patients in the studies...
Today's Sponsors
Today's Sponsor